—
C+
C+ The full Closelook — membership. Open the C+ overview

CG Oncology, Inc. Common stock (CGON) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — CG Oncology, Inc. Common stock

CGON in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
CG Oncology develops cretostimogene, an experimental virus-based immunotherapy that trains the immune system to attack bladder tumours after standard BCG treatment fails. The company runs several late-stage trials testing the therapy alone in different bladder-cancer stages, from high-risk disease to intermediate-risk cases after surgery. It has no approved product yet and generates no product revenue, relying on trial data to support future approval filings. It is based in Dallas and listed in New York.
Where it sits in the stack
CG Oncology carries no seat in Rubin, our AI-buildout index, and none in Halo; it sits outside the AI stack entirely. In our universe it belongs to the Healthcare/Biotechnology sleeve, where the diary follows clinical-stage names on trial catalysts rather than build-out exposure.
Who it is priced against
Closelook has not set a peer group for this name; the comparison the market draws is with other bladder-cancer immunotherapy developers working on alternatives to standard BCG treatment.
Why Closelook tracks it
CG Oncology holds no Rubin or Halo seat and carries no Closelook score, so no module can be named as strongest or weakest. It appears in the diary only as an occasional single-name entry, without editions or quotes tied to it.
What the diary watches
Whether upcoming trial readouts for cretostimogene, across its bladder-cancer studies, shift the stock enough to justify closer coverage.

CG Oncology, Inc. Common stock (CGON) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 45/100 composite (momentum 80, quality 2, valuation 5) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for CGON, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against CGON on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What CGON pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +23.7% in FY2025 27 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is CG Oncology, Inc. Common stock (CGON)?

CG Oncology, Inc. Common stock trades as CGON on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is CGON in a Closelook index?

Not currently — CG Oncology, Inc. Common stock is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is CG Oncology, Inc. Common stock's Closelook composite score?

45 out of 100, with momentum 80, quality 2 and valuation 5 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does CGON trade against its moving averages?

Uptrend stack intact: Trades +4.7% vs the 50-day and +23.8% vs the 200-day average, 4% below the 52-week high and +118.1% off the 52-week low. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does CG Oncology, Inc. Common stock do?

CG Oncology develops cretostimogene, an experimental virus-based immunotherapy that trains the immune system to attack bladder tumours after standard BCG treatment fails. The company runs several late-stage trials testing the therapy alone in different bladder-cancer stages, from high-risk disease to intermediate-risk cases after surgery. It has no approved product yet and generates no product revenue, relying on trial data to support future approval filings. Closelook has not set a peer group for this name; the comparison the market draws is with other bladder-cancer immunotherapy developers working on alternatives to standard BCG treatment.

Where does CG Oncology, Inc. Common stock sit in the AI build-out?

CG Oncology carries no seat in Rubin, our AI-buildout index, and none in Halo; it sits outside the AI stack entirely. In our universe it belongs to the Healthcare/Biotechnology sleeve, where the diary follows clinical-stage names on trial catalysts rather than build-out exposure. CG Oncology holds no Rubin or Halo seat and carries no Closelook score, so no module can be named as strongest or weakest. It appears in the diary only as an occasional single-name entry, without editions or quotes tied to it.

Does CG Oncology, Inc. Common stock pay a dividend?

No cash distribution shows in CG Oncology, Inc. Common stock’s price series over the last three years. The share count rose 23.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for CGON, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.